You are now leaving the Lilly Medical website
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Inluriyo ™ (imlunestrant) tablets
200 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Can Inluriyo™ (imlunestrant) be used with Zepbound® (tirzepatide)?
There is no information available on the use of Inluriyo (imlunestrant) in combination with Zepbound (tirzepatide) because this combination has not been assessed in clinical studies.
Use of Imlunestrant With Tirzepatide
Safety and Efficacy
There are no available safety or efficacy data on the use of imlunestrant in combination with tirzepatide.1
Contraindication
There are no known contraindications for the concomitant use of imlunestrant in combination with tirzepatide.1
Drug-Drug Interaction
No drug-drug interaction studies have been conducted between imlunestrant and tirzepatide.1
Enclosed Prescribing Information
Reference
1Inluriyo [package insert]. Indianapolis, IN: Eli Lilly and Company; 2025.
Date of Last Review: July 22, 2025